<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452569</url>
  </required_header>
  <id_info>
    <org_study_id>THA PH INT 2005 CL001</org_study_id>
    <nct_id>NCT00452569</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the time to progression (TTP) of three daily doses of
      thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory
      multiple myeloma (MM) patients and to subsequently select the optimum thalidomide dose in
      terms of median TPP and toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of Independent Review Committee-documented time to progression (TTP).</measure>
    <time_frame>&gt;160 &quot;IRC confirmed&quot; disease progression in the Dexamethasone or Thalidomide 400 mg/day arms</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR + PR), according to the EBMT criteria</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit as measured by ECOG performance status, transfusion requirement and Grade ≥3 infections (assessed by the National Cancer Institute Common Toxicity Criteria)</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Disease progression evaluated every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Evaluated after 150 deaths occurring in Dexamethasone and Thalidomide 400 mg arms</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death)</measure>
    <time_frame>Evaluated after 160 &quot;IRC confirmed&quot; disease progression in the Dexamethasone or Thalidomide 400 mg/day arms</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline/Week 8/ Week 16/Week 24/Week 32/Week 40/Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of peripheral neuropathy</measure>
    <time_frame>Screening, Week 24, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and physical examination</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">499</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, aged ≥ 18 years at the time of signing the informed consent
             form

          -  Patients who have been previously diagnosed with MM who have received between 1 &amp; 3
             prior lines of treatment for their disease, and who require therapy because of disease
             progression

          -  Secretory MM with measurable levels of monoclonal protein in serum (&gt; 10 g/L of IgG
             M-protein or &gt; 5 g/L of IgA M-protein) or urine (≥ 200 mg/ 24hours); Patient with the
             following rare subclasses of the immunoglobulin: IgD, IgE, IgM can be included in the
             study if the level of monoclonal protein in serum is &gt; 5g/L or ≥ 200 mg/24hours in
             urine. As IgM immunoglobulin isotype can be related to Waldenstrom's
             macroglobulinemia, it is important to distinguish and not include in the study
             patients with Waldenstrom's macroglobulinemia.

          -  ECOG performance status of 0, 1, or 2

          -  Life expectancy &gt;3months

          -  Able to adhere to the study visit schedule &amp; other protocol requirements

          -  Women of child-bearing potential must agree to use 2 methods of contraception for at
             least 4weeks before starting the therapy, during the Treatment Period, &amp; for 4 weeks
             after the last dose

          -  Males must agree to use barrier contraception (latex condoms) when engaging in
             reproductive activity during the Treatment Period &amp; for 4 weeks after the last dose

          -  Written, informed consent

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the patient from signing the Informed Consent Form

          -  Pregnant or lactating women. A serum β-hCG pregnancy test must be performed at the
             Screening visit for female patients of child-bearing potential. If the test is
             positive, the patient must be excluded from the study. Confirmation that the patient
             is not pregnant must be established by a negative serum or urinary pregnancy test with
             the result obtained 1day prior to the Baseline visit (or the day of the visit if
             results are available before drug delivery). A pregnancy test is not required for
             naturally post-menopausal women (who have not had menses at any time in the preceding
             24 consecutive months) or surgically sterilized women (hysterectomy, bilateral
             ovariectomy, bilateral salpingectomy)

          -  Non-secretory MM

          -  Any of the following laboratory abnormalities: Absolute neutrophil count (ANC) &lt;500
             cells/mm3 (0.5 x 109/L); Platelet count &lt;30,000/mm3 (30.0 x 109L) without transfusion
             support within 7 days before the test; Serum creatinine &gt;3.0mg/dL (265μmol/L); Serum
             aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) &gt;3.0 x upper
             limit of normal (ULN); Serum total bilirubin &gt;2.0mg/dL (34μmol/L)

          -  Any condition, including the presence of laboratory abnormalities, which places the
             patient at unacceptable risk if s/he were to participate in the study, or which
             confounds the ability to interpret data from the study

          -  Severe cardiac dysfunction (according to the New York Heart Association [NYHA]
             classification III-IV)

          -  Severe bradycardia (&lt;50bpm)

          -  Peripheral neuropathy ≥Grade 2 in severity (according to the NCI CTC Version 3.0)

          -  Prior history of malignancy (except for basal cell or squamous cell carcinoma of the
             skin or carcinoma in situ of the cervix or breast) unless the patient has been free of
             disease for ≥5years

          -  Patient received any chemotherapy, corticosteroids (&gt; 10 mg/day prednisone or
             equivalent as a continuous dose) within 4 weeks before randomization

          -  Previously treated with thalidomide or thalidomide derivatives

          -  Patients refractory to high-dose dexamethasone (defined as experiencing less than a PR
             to dexamethasone, or PD within 6months after discontinuing dexamethasone, or
             discontinued dexamethasone because of ≥Grade 3 dexamethasone-related toxicity.
             Previous high-dose dexamethasone therapy is defined as &gt;500mg dexamethasone or
             equivalent over a 10week period, whether administered alone or as part of the VAD
             regimen)

          -  Contraindications for high-dose dexamethasone

          -  Active or chronic gastrointestinal ulcers, active viral infections (herpes, varicella,
             HIV, hepatitis B, hepatitis C), glaucoma, uncontrolled hypertension, or diabetes
             mellitus, unless well controlled &amp; under strict supervision during dexamethasone
             treatment

          -  Patient enrolled in another clinical trial or who have participated in another trial
             with the last 4weeks before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Kropff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum Munster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Haematology, University Multiprofiled Hospital for Active Treatment &quot;G. Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Haematology, University Multiprofiled Hospital for Active Treatment</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Multiprofiled Hospital for Active Treatment &quot;Alexandrovska&quot; - Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy/Dept Haematology and Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Haematology &amp; Transfusiology</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Haematology, Multiprofiled Hospital for Active Treatment &quot;Sveta Marina&quot;</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki Bolnicki Centar Rijeka Interna Klinika</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Bolnica SPLIT - Klinika za Unutarnje Bolesti</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Zagreb - Klinika za Unutarnje Bolesti</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka Bolnica &quot;Dubrava&quot; Klinika za Unutarnje Bolesti</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka Bolnica &quot;Sestre milosrdnice&quot; Klinika za Unutarnje Bolesti</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka Bolnica MERKUR - Klinika za Unutarnje Bolesti</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interni Hemato-Onkologicka Klinika</name>
      <address>
        <city>Brno</city>
        <zip>20 625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologicka Klinika, Fakultni Nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>48 500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologicke Centrum J.G. Mendela</name>
      <address>
        <city>Novi Jicin</city>
        <zip>73601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interni Klinika, Oddeleni Hematoonkologie</name>
      <address>
        <city>Olomouc</city>
        <zip>6 775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologicka Klinika, Fakultni Nemocnice Kralovske Vinohrady Srobarova</name>
      <address>
        <city>Prague 10</city>
        <zip>50 100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interni Klinika, Oddeleni Hematoonkologie</name>
      <address>
        <city>Prague 2</city>
        <zip>2128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hopital Brabois</name>
      <address>
        <city>Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologie - CHU Purpan Place du Dr. Baylac</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite, Universitatsmedizin Berlin, Campus Robert-Rossle Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Klinik I/University Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I/Carl-Gustav-Carus University</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology, Oncology &amp; Clinical Immunology/Heinrich-Heine-University</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. Haematologie - Onkologie/ Allg. Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeinse Krankenhaus St. Georg Hamatologische Abteilung</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik Abteilung Innere V/Universitatsklinikum</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Schleswig Holstein II Med. Klinik</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik - Klinik fur innere Medizin</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik III/Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innere Medizin University Hospital</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung Haematologie - Univeresitaetsklinikum</name>
      <address>
        <city>Saale</city>
        <zip>D-06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus GmbH, Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik - Abteilung Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Klinik II/Klinikum of the Julius-Maximilians-University</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Centre Dpt Haematology</name>
      <address>
        <city>Budapest</city>
        <zip>351135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz, II. Belgyogyaszat</name>
      <address>
        <city>Gyor</city>
        <zip>H-9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman Megyei Korhaz, Megyei Onkologiai Centrum</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent-Gyorgyi Albert University II Clinic of Internal Medicine</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences, Department of Medical Oncology</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kerala</city>
        <zip>682 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchid Nursing Home</name>
      <address>
        <city>Kolkata</city>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Dayanand Medical College DMCH</name>
      <address>
        <city>Ludhiana</city>
        <zip>141 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology/Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, S.L. Raheja Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Jaslok Hospital and Research Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Deenanath Mangeshkar Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology/Regional Cancer Centre</name>
      <address>
        <city>Trivandrum</city>
        <zip>695 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto di Ematologia e Oncologia Medica</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Medicina ed Oncologia Sperimentale - Divisione Universitaria di Ematologia Azienda Ospedaliera S. Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>310126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine - Baguio General Hospital &amp; Medical Center</name>
      <address>
        <city>Baguio City</city>
        <zip>2600</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chong Hua Hospital</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Clinic Makati Medical Center</name>
      <address>
        <city>Makati City</city>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sto Tomas Hospital</name>
      <address>
        <city>Manila City</city>
        <zip>1108</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Clinic - National Kidney &amp; Transplant Institute</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK, Klinika Hematologii Akademii Medycznej</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Akademii Medycznej w Gdanskuul</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematologii i Transplantacji Szpiku - Slaska Akademia Medyczna</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swietokrzyskie Centrum Onkologii SPZOZ Poradnia Hematologii</name>
      <address>
        <city>Kielce</city>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Uniwersytetu Medycznego</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chorob Wewnetrznych i Hemagologii</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematologii, Onkologii I Chorob Wewnetrznych</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii - Klinika Hematologiczna</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Nowotworow Krwi i Transplantacji - Szpiku Akademii Medycznej</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Universidade de Coimbra - Servico de Hematologia Clinica</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Santo Antonio - Servico de Hematologia Clinica</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology, Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Hematology, Clinical Centre Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Hematology, Clinical Centre Novi Sad</name>
      <address>
        <city>Novisad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, National Cancer Institute</name>
      <address>
        <city>Bratilslava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Department University Hospital</name>
      <address>
        <city>Bratilslava</city>
        <zip>85107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Department, University Hospital PJS</name>
      <address>
        <city>Kosice</city>
        <zip>04066</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Free State, Faculty of Health Science, Dept of Hematology &amp; Cell Biology</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital, University of Stellenbosch, Department of Haematology</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, UCT Medical School</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital, Clinical Haematology Unit</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Centre of Rosebank</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannesburg Hospital, Department of Medical Oncology</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Research Unit Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B95 SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Haematology, Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology Department - King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology-Oncology, The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <reference>
    <citation>Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Bladé J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012 May;97(5):784-91. doi: 10.3324/haematol.2011.044271. Epub 2011 Dec 1.</citation>
    <PMID>22133776</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

